Antibody-drug conjugate · Cytotoxic, directed at B7-H4 (VTCN1) · developed by NextCure
LNCB74 is an antibody-drug conjugate that binds B7-H4, a checkpoint ligand expressed on tumor cells and tumor-associated macrophages. After internalization, the linked MMAE payload is released by beta-glucuronidase and disrupts microtubule polymerization. It is being studied in advanced solid tumors, including ovarian, breast, endometrial, biliary tract and non-small cell lung cancers.
Summary written with AI from the sources listed at the end of this page.
Advanced or Metastatic Solid TumorsBiliary Tract CancerBreast CancerEndometrial CancerNon-Small Cell Lung CancerOvarian Cancer
Updated Oct 25, 2026. Something wrong or missing? Report it on the NXTC page.
See NXTC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NXTC catalysts and pipeline →